drugset / Trial / NCT03329248
QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b/2 study to evaluate the safety and efficacy of metronomic combination therapy in subjects with pancreatic cancer who have progressed on or after previous SoC chemotherapy. Phase 2 will be based on Simon's two-stage optimal design.
Timeline
- Start
- 2017-11-06
- Primary completion
- 2018-08-13
- Completion
- 2019-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avelumab | Monoclonal antibody | — | — |
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | — | — |
| Subject | ETBX-011 | Vaccine | — | — |
| Subject | GI-4000 | Vaccine | — | — |
| Subject | Leucovorin | Small molecule | — | — |
| Subject | Lovaza | Other / unclassified | — | — |
| Subject | N-803 | Protein / enzyme biologic | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Paclitaxel | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |
| Subject | haNK | Cell therapy | — | — |